Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- ...
SAN FRANCISCO — Among patients with symptomatic, severe native aortic regurgitation at high surgical risk, the JenaValve Trilogy transcatheter heart valve system (JenaValve Technology) met its primary ...
WASHINGTON — A phase 3 randomized trial will soon begin for the first transcatheter aortic valve replacement (TAVR) device for the treatment of aortic valve regurgitation after promising results in a ...
Please provide your email address to receive an email when new articles are posted on . A transcatheter aortic valve replacement system designed to treat aortic regurgitation exceeded its safety and ...
NEW YORK, NY—For patients with pure native aortic regurgitation (AR) who are undergoing TAVI, use of devices tailored to treat the AR seems to provide superior outcomes compared with off-label use of ...
Among young adults with aortic regurgitation (AR), those undergoing aortic valve replacement (AVR) before they met standard criteria were more likely to achieve good results from the surgery, a study ...
Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had an overall mortality rate of just 8.1% at one year, well below the trial's ...
RA was tied to an increased risk of aortic stenosis, aortic regurgitation, and mitral regurgitation, independent of other cardiovascular risk factors. Women and younger patients with RA face a higher ...
Valvular regurgitation is when blood flows backward through the chambers of your heart. It can be mild and not cause symptoms, or it can be life threatening. Your heart is a muscular organ that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results